Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes-Reference-Cited by-同舟云学术

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

Published:2024-05 Issue:5 Volume:35 Page:458-472
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Olmos D.^ORCID,Lorente D.,Alameda D.^ORCID,Cattrini C.,Romero-Laorden N.^ORCID,Lozano R.,Lopez-Casas P.P.,Jambrina A.,Capone C.,Vanden Broecke A.M.,Trevisan M.^ORCID,Van Sanden S.,Jürgens A.,Herrera-Imbroda B.,Castro E.

Publisher

Elsevier BV

Reference41 articles.

1. Integrative clinical genomics of advanced prostate cancer;Robinson;Cell,2015

2. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making;Abida;JCO Precis Oncol,2017

3. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA;Schweizer;JAMA Oncol,2021

4. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations;Kuzbari;Ann Oncol,2023

5. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer;Castro;J Clin Oncol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer;European Journal of Cancer;2024-09

2. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer;Drugs;2024-07-26

3. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real‐world setting of metastatic prostate cancer;BJU International;2024-07-10

4. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer;Advances in Therapy;2024-07-03

5. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations;The Oncologist;2024-06-17